A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Impact of Disease questionnaire (PsAID-12) scores were associated with treatment escalation, physicians primarily relied on clinical assessments when making treatment decisions.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Lorna Staines discusses a longitudinal population-based study examining the risks of using psychedelics in a naturalistic ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback